Skip to main content
×
Home
    • Aa
    • Aa

ASPIRIN ADMINISTRATION FOR PREVENTION OF ADVERSE PREGNANCY OUTCOMES

  • EMMANUEL BUJOLD (a1), STÉPHANIE ROBERGE (a1), SUZANNE DEMERS (a1) and KYPROS H NICOLAIDES (a2)
Abstract

The prophylactic use of low-dose aspirin for prevention of preeclampsia has been an important research question in obstetrics for the last three decades. In 1979, Crandon and Isherwood observed that nulliparous women who had taken aspirin regularly during pregnancy were less likely to have preeclampsia than women who did not. In 1985, Beaufils et al published the first randomized trial suggesting that 150 mg aspirin and 300 mg dipyridamole daily from 3 months’ gestation onwards decreased the risk of preeclampsia, fetal growth restriction and stillbirth in high-risk women. Subsequently, more than 50 trials have been carried out throughout the world and a meta-analysis of these studies reported that the administration of low-dose aspirin in high-risk pregnancies is associated with a decrease in the rate of preeclampsia by approximately 10%. Consequently, several national professional bodies recommend that high-risk pregnancies should be treated with aspirin (50–150 mg daily).

Copyright
Corresponding author
Emmanuel Bujold, MD, MSc, FRCSC, Associate Professor, Department of Obstetrics and Gynecology and Social and Preventive Medicine, Faculty of Medicine, Université Laval, 2705 boulevard Laurier, Québec City, QC, Canada, G1V 4G2. email: emmanuel.bujold@crchul.ulaval.ca
References
Hide All
1Crandon AJ, Isherwood DM. Effect of aspirin on incidence of pre-eclampsia. Lancet. 1979; 1: 1356.
2Beaufils M, Uzan S, Donsimoni R, Colau JC. Prevention of pre-eclampsia by early antiplatelet therapy. Lancet 1985; 1: 840–42.
3Askie LM, Duley L, Henderson-Smart DJ, Stewart LA. Antiplatelet agents for prevention of pre-eclampsia: A meta-analysis of individual patient data. Lancet 2007; 369: 1791–798.
4Magee LA, Helewa M, Moutquin JM, von Dadelszen P. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol Can 2008; 30: S1–48.
5National Collaborating Centre for Women's and Children's Health. Commissioned by the national institute for health and clinical excellence. Hypertension in pregnancy: The management of hypertensive disorders during pregnancy. Cg107. 2011.
6Lowe SA, Brown MA, Dekker GA, Gatt S, McLintock CK, McMahon LP et al.Guidelines for the management of hypertensive disorders of pregnancy 2008. Aust N Z J Obstet Gynaecol 2009; 49: 242–46.
7Ministry of health report. 1929. Memorandum on antenatal clinics: Their conduct and scope. His Majesty's Stationery Office. London. 1930.
8Nicolaides KH. Turning the pyramid of prenatal care. Fetal Diagn Ther 2011; 29: 183–96.
9Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S et al.Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: A meta-analysis. Obstet Gynecol 2010; 116: 402–14.
10Bujold E, Roberge S, Tapp S, Giguere Y. Opinion & hypothesis could early aspirin prophylaxis prevent against preterm birth? J Matern Fetal Neonatal Med 2011; 24: 966–67.
11Mesdaghinia E, Talari H, Abedzadeh-Kalahroudi M. Effect of aspirin for prevention of preeclampsia in women with abnormal ultrasonic findings in uterine artery. Feyz 2011; 15: 98104. http://feyz.hbi.ir/index.php?slc_lang=en&sid=1
12Villa P, Taipale P, Räikkönen K, Hämäläinen E, Pesonen A, Kajantie E et al. Predo trial- acetylsalicylic acid in preventing pre-eclampsia in high-risk women. Pregnancy Hypertension 2010: S1–41.
13Villa PM, Kajantie E, Räikkönen K, Pesonen A-K, Hämäläinen E, Vainio M et al. Aspirin in the prevention of pre-eclampsia in high-risk women: A randomised placebocontrolled PREDO trial and a meta-analysis of randomised trials. BJOG in press
14Bakhti A, Vaiman D. Prevention of gravidic endothelial hypertension by aspirin treatment administered from the 8th week of gestation. Hypertension Research 2011; 34: 1116–120.
15August P, Helseth G, Edersheim T, Hutson J, Druzin M. Sustained relase, low-dose aspirin ameliorates but does not prevent preeclampsia (pe) in a high risk population. Proceedings of 9th International Congress, International Society for the Study of Hypertension. 1994: 72.
16Azar R, Turpin D. Effect of antiplatelet therapy in women at high risk for pregnancy-induced hypertension. Proceedings of 7th World Congress of Hypertension in Pregnancy. 1990: 257.
17Benigni A, Gregorini G, Frusca T, Chiabrando C, Ballerini S, Valcamonico A et al.Effect of low-dose aspirin on fetal and maternal generation of thromboxane by platelets in women at risk for pregnancy-induced hypertension. N Engl J Med 1989; 321: 357–62.
18Ebrashy A, Ibrahim M, Marzook A, Yousef D. Usefulness of aspirin therapy in high-risk pregnant women with abnormal uterine artery doppler ultrasound at 14–16 weeks pregnancy: Randomized controlled clinical trial. Croat Med J 2005; 46: 826–31.
19Hermida RC, Ayala DE, Iglesias M, Mojon A, Silva I, Ucieda R et al.Time-dependent effects of low-dose aspirin administration on blood pressure in pregnant women. Hypertension 1997; 30: 589–95.
20Michael C, Walters B. Low-dose aspirin in the prevention of pre-eclampsia: Current evaluation. Maternal physiology and pathology. The current status of gynaecology and obstetrics serie. 1992; Maternal physiology and pathology. The current status of gynaecology and obstetrics series: 183–89.
21Tulppala M, Marttunen M, Soderstrom-Anttila V, Foudila T, Ailus K, Palosuo T et al.Low-dose aspirin in prevention of miscarriage in women with unexplained or autoimmune related recurrent miscarriage: Effect on prostacyclin and thromboxane a2 production. Hum Reprod 1997; 12: 1567–572.
22Vainio M, Kujansuu E, Iso-Mustajarvi M, Maenpaa J. Low dose acetylsalicylic acid in prevention of pregnancy-induced hypertension and intrauterine growth retardation in women with bilateral uterine artery notches. BJOG 2002; 109: 161–67.
23Roberge S, Villa P, Nicolaides K, Giguere Y, Vainio M, Bakthi A et al.Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: A systematic review and meta-analysis. Fetal Diagn Ther 2012; 31: 141–46.
24Roberge S, Giguere Y, Villa P, Nicolaides K, Vainio M, Forest JC et al. Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: A systematic review and meta-analysis. Am J Perinatol 2012; 29: 551–56.
25Clasp: A randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. Clasp (collaborative low-dose aspirin study in pregnancy) collaborative group. Lancet 1994; 343: 619–29.
26Moldenhauer JS, Stanek J, Warshak C, Khoury J, Sibai B. The frequency and severity of placental findings in women with preeclampsia are gestational age dependent. Am J Obstet Gynecol 2003; 189: 1173–177.
27Sebire NJ, Goldin RD, Regan L. Term preeclampsia is associated with minimal histopathological placental features regardless of clinical severity. J Obstet Gynaecol. 2005; 25: 117–18.
28Vatten LJ, Skjaerven R. Is pre-eclampsia more than one disease? BJOG 2004; 111: 298302.
29Xiong X, Demianczuk NN, Saunders LD, Wang FL, Fraser WD. Impact of preeclampsia and gestational hypertension on birth weight by gestational age. Am J Epidemiol 2002; 155: 203209.
30Odegard RA, Vatten LJ, Nilsen ST, Salvesen KA, Austgulen R. Preeclampsia and fetal growth. Obstet Gynecol 2000; 96: 950–55.
31Xiao R, Sorensen TK, Williams MA, Luthy DA. Influence of pre-eclampsia on fetal growth. J Matern Fetal Neonatal Med 2003; 13: 157–62.
32Yu CK, Khouri O, Onwudiwe N, Spiliopoulos Y, Nicolaides KH. Prediction of pre-eclampsia by uterine artery doppler imaging: Relationship to gestational age at delivery and small-for-gestational age. Ultrasound Obstet Gynecol 2008; 31: 310–13.
33Groeneveld E, Broeze KA, Lambers MJ, Haapsamo M, Dirckx K, Schoot BC et al.Is aspirin effective in women undergoing in vitro fertilization (IVF)? Results from an individual patient data meta-analysis (IPD MA). Hum Reprod Update 2011; 17: 501509.
34Lambers MJ, Groeneveld E, Hoozemans DA, Schats R, Homburg R, Lambalk CB et al.Lower incidence of hypertensive complications during pregnancy in patients treated with low-dose aspirin during in vitro fertilization and early pregnancy. Hum Reprod 2009; 24: 2447–450.
35Haapsamo M, Martikainen H, Tinkanen H, Heinonen S, Nuojua-Huttunen S, Rasanen J. Low-dose aspirin therapy and hypertensive pregnancy complications in unselected IVF and ICSI patients: A randomized, placebo-controlled, double-blind study. Hum Reprod 2010; 25: 2972–977.
36Kaandorp SP, Goddijn M, van der Post JA, Hutten BA, Verhoeve HR, Hamulyak K et al.Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med 2010; 362: 1586–596.
37Siristatidis CS, Dodd SR, Drakeley AJ. Aspirin is not recommended for women undergoing IVF. Hum Reprod Update 2012; 18: 233.
38Masotti G, Galanti G, Poggesi L, Abbate R, Neri Serneri GG. Differential inhibition of prostacyclin production and platelet aggregation by aspirin. Lancet. 1979; 2: 1213–217.
39Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet 2010; 376: 631–44.
40Brosens IA. Morphological changes in the utero-placental bed in pregnancy hypertension. Clin Obstet Gynaecol 1977; 4: 573–93.
41Pijnenborg R, Dixon G, Robertson WB, Brosens I. Trophoblastic invasion of human decidua from 8 to 18 weeks of pregnancy. Placenta 1980; 1: 319
42Haapsamo M, Martikainen H, Rasanen J. Low-dose aspirin reduces uteroplacental vascular impedance in early and mid gestation in IVF and ICSI patients: A randomized, placebo-controlled double-blind study. Ultrasound Obstet Gynecol 2008; 32: 687–93.
43Kim YM, Bujold E, Chaiworapongsa T, Gomez R, Yoon BH, Thaler HT et al.Failure of physiologic transformation of the spiral arteries in patients with preterm labor and intact membranes. Am J Obstet Gynecol 2003; 189: 10631069.
44Kim YM, Chaiworapongsa T, Gomez R, Bujold E, Yoon BH, Rotmensch S et al.Failure of physiologic transformation of the spiral arteries in the placental bed in preterm premature rupture of membranes. Am J Obstet Gynecol 2002; 187: 1137–142.
45Lewis RB, Schulman JD. Influence of acetylsalicylic acid, an inhibitor of prostaglandin synthesis, on the duration of human gestation and labour. Lancet 1973; 2: 1159–161.
46Slone D, Siskind V, Heinonen OP, Monson RR, Kaufman DW, Shapiro S. Aspirin and congenital malformations. Lancet 1976; 1: 1373–375.
47Werler MM, Mitchell AA, Shapiro S. The relation of aspirin use during the first trimester of pregnancy to congenital cardiac defects. N Engl J Med 1989; 321: 16391642.
48Norgard B, Puho E, Czeizel AE, Skriver MV, Sorensen HT. Aspirin use during early pregnancy and the risk of congenital abnormalities: A population-based case-control study. Am J Obstet Gynecol 2005; 192: 922–23.
49Klebanoff MA, Berendes HW. Aspirin exposure during the first 20 weeks of gestation and IQ at four years of age. Teratology 1988; 37: 249255.
50Keim SA, Klebanoff MA. Aspirin use and miscarriage risk. Epidemiology 2006; 17: 435–39.
51Hernandez RK, Werler MM, Romitti P, Sun L, Anderka M. Nonsteroidal antiinflammatory drug use among women and the risk of birth defects. Am J Obstet Gynecol 2011; 206: 228.
52Levy G, Procknal JA, Garrettson LK. Distribution of salicylate between neonatal and maternal serum at diffusion equilibrium. Clin Pharmacol Ther 1975; 18: 210–14.
53Levy G, Garrettson LK. Kinetics of salicylate elimination by newborn infants of mothers who ingested aspirin before delivery. Pediatrics 1974; 53: 201–10.
54Sibai BM, Mirro R, Chesney CM, Leffler C. Low-dose aspirin in pregnancy. Obstet Gynecol 1989; 74: 551–57.
55Schiessl B, Schneider KT, Zimmermann A, Kainer F, Friese K, Oberhoffer R. Prenatal constriction of the fetal ductus arteriosus–related to maternal pain medication? Z Geburtshilfe Neonatol 2005; 209: 6568.
56Wyatt-Ashmead J. Antenatal closure of the ductus arteriosus and hydrops fetalis. Pediatr Dev Pathol 2011; 14: 469–74.
57Di Sessa TG, Moretti ML, Khoury A, Pulliam DA, Arheart KL, Sibai BM. Cardiac function in fetuses and newborns exposed to low-dose aspirin during pregnancy. Am J Obstet Gynecol 1994; 171: 892900.
58Leonhardt A, Bernert S, Watzer B, Schmitz-Ziegler G, Seyberth HW. Low-dose aspirin in pregnancy: Maternal and neonatal aspirin concentrations and neonatal prostanoid formation. Pediatrics 2003; 111: e7781.
59Bleyer WA, Breckenridge RT. Studies on the detection of adverse drug reactions in the newborn. II. The effects of prenatal aspirin on newborn hemostasis. JAMA. 1970; 213: 20492053.
60Corby DG, Schulman I. The effects of antenatal drug administration on aggregation of platelets of newborn infants. J Pediatr 1971; 79: 307–13.
61Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007: CD004659.
62Rotchell YE, Cruickshank JK, Gay MP, Griffiths J, Stewart A, Farrell B et al.Barbados low dose aspirin study in pregnancy (blasp): A randomised trial for the prevention of pre-eclampsia and its complications. Br J Obstet Gynaecol 1998; 105: 286–92.
63Sibai BM, Caritis SN, Thom E, Klebanoff M, McNellis D, Rocco L et al.Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. The national institute of child health and human development network of maternal-fetal medicine units. N Engl J Med. 1993; 329: 1213–218.
64Caritis S, Sibai B, Hauth J, Lindheimer MD, Klebanoff M, Thom E et al.Low-dose aspirin to prevent preeclampsia in women at high risk. National institute of child health and human development network of maternal-fetal medicine units. N Engl J Med 1998; 338: 701705.
65Subtil D, Goeusse P, Puech F, Lequien P, Biausque S, Breart G et al.Aspirin (100 mg) used for prevention of pre-eclampsia in nulliparous women: The essai regional aspirine mere-enfant study (part 1). BJOG 2003; 110: 475–84.
66Hauth JC, Goldenberg RL, Parker CR Jr., Cutter GR, Cliver SP. Low-dose aspirin: Lack of association with an increase in abruptio placentae or perinatal mortality. Obstet Gynecol 1995; 85: 10551058
67Sibai BM, Caritis SN, Thom E, Shaw K, McNellis D. Low-dose aspirin in nulliparous women: Safety of continuous epidural block and correlation between bleeding time and maternal-neonatal bleeding complications. National institute of child health and human developmental maternal-fetal medicine network. Am J Obstet Gynecol 1995; 172: 1553–557.
68Caron N, Rivard GE, Michon N, Morin F, Pilon D, Moutquin JM, Rey E. Low-dose asa response using the pfa-100 in women with high-risk pregnancy. J Obstet Gynaecol 2009; 31: 10221027.
69Rey E, Rivard GE. Is testing for aspirin response worthwhile in high-risk pregnancy? Eur J Obstet Gynecol Reprod Biol 2011; 157: 3842.
70Vainio M, Maenpaa J, Riutta A, Ylitalo P, Ala-Fossi SL, Tuimala R. In the dose range of 0.5–2.0 mg/kg, acetylsalicylic acid does not affect prostacyclin production in hypertensive pregnancies. Acta Obstet Gynecol Scand 1999; 78: 8288
71Dumont A, Flahault A, Beaufils M, Verdy E, Uzan S. Effect of aspirin in pregnant women is dependent on increase in bleeding time. Am J Obstet Gynecol 1999; 180: 135–40.
72Wojtowicz A, Undas A, Huras H, Musial J, Rytlewski K, Reron A et al.Aspirin resistance may be associated with adverse pregnancy outcomes. Neuro Endocrinol Lett 2011; 32: 334–39.
73Homoncik M, Jilma B, Hergovich N, Stohlawetz P, Panzer S, Speiser W. Monitoring of aspirin (asa) pharmacodynamics with the platelet function analyzer pfa-100. Thromb Haemost 2000; 83: 316–21.
74Spencer K, Yu CK, Cowans NJ, Otigbah C, Nicolaides KH. Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free BETA-HCG and with second-trimester uterine artery doppler. Prenat Diagn 2005; 25: 949–53.
75Poon LC, Kametas NA, Valencia C, Chelemen T, Nicolaides KH. Hypertensive disorders in pregnancy: Screening by systolic diastolic and mean arterial` pressure at 11–13 weeks. Hypertens Pregnancy 2011; 30: 93107.
76Akolekar R, Etchegaray A, Zhou Y, Maiz N, Nicolaides KH. Maternal serum activin a at 11–13 weeks of gestation in hypertensive disorders of pregnancy. Fetal Diagn Ther 2009; 25: 320–27.
77Akolekar R, Minekawa R, Veduta A, Romero XC, Nicolaides KH. Maternal plasma inhibin a at 11–13 weeks of gestation in hypertensive disorders of pregnancy. Prenat Diagn. 2009; 29: 753–60.
78Akolekar R, Syngelaki A, Beta J, Kocylowski R, Nicolaides KH. Maternal serum placental protein 13 at 11–13 weeks of gestation in preeclampsia. Prenat Diagn 2009; 29: 1103–108.
79Karagiannis G, Akolekar R, Sarquis R, Wright D, Nicolaides KH. Prediction of small-for-gestation neonates from biophysical and biochemical markers at 11–13 weeks. Fetal Diagn Ther 2011; 29: 148–54.
80Poon LC, Kametas NA, Chelemen T, Leal A, Nicolaides KH. Maternal risk factors for hypertensive disorders in pregnancy: A multivariate approach. J Hum Hypertens 2010; 24: 104–10.
81Poon LC, Kametas NA, Maiz N, Akolekar R, Nicolaides KH. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension 2009; 53: 812–18.
82Poon LC, Kametas NA, Pandeva I, Valencia C, Nicolaides KH. Mean arterial pressure at 11(+0) to 13(+6) weeks in the prediction of preeclampsia. Hypertension 2008; 51: 10271033
83Syngelaki A, Bredaki FE, Vaikousi E, Maiz N, Nicolaides KH. Body mass index at 11–13 weeks’ gestation and pregnancy complications. Fetal Diagn Ther 2011; 30: 250–65.
84Smith GC, Yu CK, Papageorghiou AT, Cacho AM, Nicolaides KH. Maternal uterine artery doppler flow velocimetry and the risk of stillbirth. Obstet Gynecol. 2007; 109: 144–51.
85Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11–13 weeks. Prenat Diagn 2011; 1: 6674
86Giguere Y, Charland M, Bujold E, Bernard N, Grenier S, Rousseau F et al.Combining biochemical and ultrasonographic markers in predicting preeclampsia: A systematic review. Clin Chem 2010; 56: 361–75.
87Bujold E, Morency AM, Roberge S, Lacasse Y, Forest JC, Giguere Y. Acetylsalicylic acid for the prevention of preeclampsia and intra-uterine growth restriction in women with abnormal uterine artery doppler: A systematic review and meta-analysis. J Obstet Gynaecol Can 2009; 31: 818–26.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Fetal and Maternal Medicine Review
  • ISSN: 0965-5395
  • EISSN: 1469-5065
  • URL: /core/journals/fetal-and-maternal-medicine-review
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 8 *
Loading metrics...

Abstract views

Total abstract views: 100 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 19th October 2017. This data will be updated every 24 hours.